SARS-CoV-2 Neutralizing Antibodies in Chile after a Vaccination Campaign with Five Different Schemes

被引：4

作者：

Aguilera, Ximena ^{[1
]}

Hormazabal, Juan ^{[2
]}

Vial, Cecilia ^{[2
]}

Jimena Cortes, Lina ^{[2
]}

Gonzalez, Claudia ^{[1
]}

Rubilar, Paola ^{[1
]}

Apablaza, Mauricio ^{[3
]}

Ramirez-Santana, Muriel ^{[4
]}

Icaza, Gloria ^{[5
]}

Nunez-Franz, Loreto ^{[6
]}

Castillo-Laborde, Carla ^{[1
]}

Ramirez-Riffo, Carolina ^{[2
]}

Perez, Claudia ^{[7
]}

Quezada-Gate, Ruben ^{[4
]}

Said, Macarena ^{[6
]}

Vial, Pablo ^{[2
,8
]}

机构：

[1] Clin Alemana Univ Desarrollo, Ctr Epidemiol & Polit Salud, Fac Med, Av Plaza 680, Santiago 7610658, Chile

[2] Clin Alemana Univ Desarrollo, Inst Ciencias & Innovac Med, Fac Med, Av Plaza 680, Santiago 7610658, Chile

[3] Univ Desarrollo, Fac Gobierno, Av Plaza 680, Santiago 7610658, Chile

[4] Univ Catolica Norte, Fac Med, Publ Hlth Dept, Larrondo 1281, Coquimbo 1780000, Chile

[5] Univ Talca, Inst Matemat, Ave Uno Poniente 1141, Talca 3460000, Chile

[6] Univ Talca, Fac Ciencias Salud, Dept Salud Publ, Ave Uno Poniente 1141, Talca 3460000, Chile

[7] Clin Alemana Univ Desarrollo, Fac Med, Escuela Enfermeria, Av Plaza 680, Santiago 7610658, Chile

[8] Clin Alemana Santiago, Ave Vitacura 5951, Santiago 7650568, Chile

来源：

VACCINES | 2022年 / 10卷 / 07期

关键词：

neutralizing antibodies; vaccines; BNT162b2; CoronaVac; AZD1222; COVID-19; SARS-CoV-2; cross-sectional design; vaccine-preventable diseases; viruses; COVID-19; VACCINES; BNT162B2;

D O I：

10.3390/vaccines10071051

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Using levels of neutralizing antibodies (nAbs), we evaluate the successful Chilean SARS-CoV-2 vaccine campaign, which combines different vaccine technologies and heterologous boosters. From a population-based study performed in November 2021, we randomly selected 120 seropositive individuals, organized into six groups of positive samples (20 subjects each) according to natural infection history and the five most frequent vaccination schemes. We conclude that the booster dose, regardless of vaccine technology or natural infection, and mRNA vaccines significantly improve nAbs response.

引用

页数：7

共 50 条

[31] Development of SARS-CoV-2 Specific IgG and Virus-Neutralizing Antibodies after Infection with Variants of Concern or Vaccination
Neumann, Franziska
Rose, Ruben
Roempke, Janine
Grobe, Olaf
Lorentz, Thomas
Fickenscher, Helmut
Krumbholz, Andi
VACCINES, 2021, 9 (07)
[32] Efficient Maternal to Neonate Transfer of Neutralizing Antibodies after SARS-CoV-2 Vaccination with BNT162b2: A Case-Report and Discussion of the Literature
Douxfils, Jonathan
Gillot, Constant
De Gottal, Emilie
Vandervinne, Stephanie
Bayart, Jean-Louis
Dogne, Jean-Michel
Favresse, Julien
VACCINES, 2021, 9 (08)
[33] Production of two SARS-CoV-2 neutralizing antibodies with different potencies in Nicotiana benthamiana
Frigerio, Rachele
Marusic, Carla
Villani, Maria Elena
Lico, Chiara
Capodicasa, Cristina
Andreano, Emanuele
Paciello, Ida
Rappuoli, Rino
Salzano, Anna Maria
Scaloni, Andrea
Baschieri, Selene
Donini, Marcello
FRONTIERS IN PLANT SCIENCE, 2022, 13
[34] Neutralizing antibodies targeting SARS-CoV-2 spike protein
Shi Xiaojie
Li Yu
Yan Lei
Yang Guang
Qiang Min
STEM CELL RESEARCH, 2021, 50
[35] SARS-CoV-2 vaccination and uveitis: Are they linked?
Waseem, Summaiyya
Ahmed, Syed Hassan
Fatima, Sharmeen
Shaikh, Taha Gul
Ahmed, Jawad
ANNALS OF MEDICINE AND SURGERY, 2022, 81
[36] SARS-CoV-2 Vaccination: The Time Is Now
Wiegel, Joshua J.
KIDNEY360, 2021, 2 (09): : 1402 - 1404
[37] Strategic Planning of a Joint SARS-CoV-2 and Influenza Vaccination Campaign in the UK
Ibrahim, Dauda
Kis, Zoltan
Papathanasiou, Maria M.
Kontoravdi, Cleo
Chachuat, Benoit
Shah, Nilay
VACCINES, 2024, 12 (02)
[38] Association between SARS-CoV-2 Neutralizing Antibodies and Commercial Serological Assays
Tang, Mei San
Case, James Brett
Franks, Caroline E.
Chen, Rita E.
Anderson, Neil W.
Henderson, Jeffrey P.
Diamond, Michael S.
Gronowski, Ann M.
Farnsworth, Christopher W.
CLINICAL CHEMISTRY, 2020, 66 (12) : 1538 - 1547
[39] Cross-reactive antibodies after SARS-CoV-2 infection and vaccination
Grobben, Marloes
van der Straten, Karlijn
Brouwer, Philip J. M.
Brinkkemper, Mitch
Maisonnasse, Pauline
Dereuddre-Bosquet, Nathalie
Appelman, Brent
Lovell, A. H. Ayesha
van Vught, Lonneke A.
Burger, Judith A.
Poniman, Meliawati
Oomen, Melissa
Eggink, Dirk
Bijl, Tom P. L.
van Willigen, Hugo D. G.
Wynberg, Elke
Verkaik, Bas J.
Figaroa, Orlane J. A.
de Vries, Peter J.
Boertien, Tessel M.
Bomers, Marije K.
Sikkens, Jonne J.
Le Grand, Roger
de Jong, Menno D.
Prins, Maria
Chung, Amy W.
de Bree, Godelieve J.
Sanders, Rogier W.
van Gils, Marit J.
ELIFE, 2021, 10
[40] Quantitative microfluidic assay to measure neutralizing and total antibodies for SARS-CoV-2
Bae, Hyunjun
Lee, Dain
Kim, Hana
Jee, Young Sam
Kim, Jian
Min, Byonggon
Park, Ye-Na
Seo, Joon-Seok
Lee, Jeong-min
Lee, Seongho
Kim, Juhyung
Jo, Han-Sang
Na, Kyuhwan
Chung, Seok
Suh, In Bum
SENSORS AND ACTUATORS B-CHEMICAL, 2024, 403

← 1 2 3 4 5 →